Steven Cohen Corvus Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$44.6 Billion
Q2 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 7,042,373 shares of CRVS stock, worth $51.6 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

7,042,373

Previous 2,787,631 152.63%

Holding current value

$51.6 Million

Previous $8.86 Million 217.79%

% of portfolio

0.06%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.82 - $4.5 $12 Million - $19.1 Million	4,254,742 Added 152.63%	7,042,373 $28.2 Million
Q1 2025 May 15, 2025	SELL	$3.18 - $6.03 $770,768 - $1.46 Million	-242,380 Reduced 8.0%	2,787,631 $8.86 Million
Q4 2024 Feb 14, 2025	SELL	$4.55 - $9.56 $11.5 Million - $24.2 Million	-2,532,718 Reduced 45.53%	3,030,011 $15.8 Million
Q3 2024 Nov 14, 2024	SELL	$1.78 - $5.92 $715,170 - $2.38 Million	-401,781 Reduced 6.74%	5,562,729 $29.4 Million
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $8.11 Million - $13.7 Million	5,964,510 New	5,964,510 $10.9 Million
Q2 2022 Aug 15, 2022	SELL	$0.87 - $2.03 $648,150 - $1.51 Million	-745,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $73,000 - $124,000	-50,000 Reduced 6.29%	745,000 $1.22 Million
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $514,799 - $1.17 Million	220,000 Added 38.26%	795,000 $1.92 Million
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $1.09 Million - $4.9 Million	575,000 New	575,000 $2.78 Million
Q4 2017 Feb 14, 2018	SELL	$9.3 - $16.93 $1.81 Million - $3.3 Million	-195,034 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $2.2 Million - $3.36 Million	195,034	195,034 $3.11 Million

Others Institutions Holding CRVS

# of Institutions

101

Shares Held

38.9M

Call Options Held

98.5K

Put Options Held

226K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $341M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account